Hepatocellular Carcinoma — Trials

Hepatocellular Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

3,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 693
Recruiting: 412
Ph III recruiting: 39
Growth YoY: 0%
Industry share: 23%
Top sponsor: Sun Yat-sen University
Termination share: 34.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (356)

clinicaltrialsPublishedShowing 1–50 of 160 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04123379	Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)	active not recruiting	Phase 2	48	Icahn School of Medicine at Mount SinaiOTHER	1	Sep 25, 2026	clinicaltrials
NCT06109272	A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)(LIVIGNO-2)	active not recruiting	Phase 2 / Phase 3	89	AbbVie